Articles from Ambros Therapeutics, Inc.

WALTHAM, Mass. and SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) and Ambros Therapeutics, Inc., today announced that they entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Ambros Therapeutics’ neridronate development program in Complex Regional Pain Syndrome Type 1 (“CRPS-1”, formerly known as Reflex Sympathetic Dystrophy). Upon completion of the merger, the combined company will operate as Ambros Therapeutics, headquartered in San Diego, California, and is expected to trade under the Nasdaq ticker symbol “AMBX”.

IRVINE, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- Ambros Therapeutics, Inc., today announced the appointment of Cris Calsada as Chief Financial Officer (CFO) and Claire Padgett, Ph.D., as Senior Vice President (SVP) of Clinical Operations and Program Management. Ms. Calsada will oversee the company’s finance organization, including financial strategy, capital planning, and investor relations. Dr. Padgett will oversee clinical operations and program management, including the pivotal CRPS-RISE Phase 3 clinical trial evaluating neridronate for the treatment of Complex Regional Pain Syndrome Type 1 (CRPS-1).

IRVINE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Ambros Therapeutics, Inc. today announced that the first patient has been dosed in its pivotal CRPS-RISE Phase 3 clinical trial evaluating neridronate versus placebo for the treatment of Complex Regional Pain Syndrome Type 1 (CRPS-1). CRPS-1 is a severe, debilitating rare disease with an estimated 65,000 new cases annually in the United States.

Enhances Intellectual Property Portfolio and Strengthens the Potential for Neridronate Exclusivity through 2045